Calculations at 3.33 mg/mL For a 0.25mg dose: 0.25 divided by 3.33 equals 0.075mL, which is 7.5 units on a U-100 syringe
Your first follow-up takes place 3 weeks after treatment begins, with continued clinical review to track response, manage side effects, and refine the plan over time
As with any medication, semaglutide and tirzepatide may cause side effects and are not appropriate for everyone
The most commonly reported adverse effects of semaglutide are gastrointestinal in nature, occurring in approximately 10-40% of patients according to the SmPC
Unlike semaglutide, which only mimics the effect of GLP-1 hormones, tirzepatide is a dual agonist that mimics both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)
These are the injection sites that the drug manufacturer recommends